Laurel Wealth Advisors LLC Acquires 1,477 Shares of LeMaitre Vascular, Inc. $LMAT

Laurel Wealth Advisors LLC raised its stake in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 8,205.6% in the second quarter, HoldingsChannel reports. The institutional investor owned 1,495 shares of the medical instruments supplier’s stock after acquiring an additional 1,477 shares during the period. Laurel Wealth Advisors LLC’s holdings in LeMaitre Vascular were worth $124,000 at the end of the most recent reporting period.

Other hedge funds have also recently modified their holdings of the company. Parkside Financial Bank & Trust boosted its position in shares of LeMaitre Vascular by 1,913.3% during the second quarter. Parkside Financial Bank & Trust now owns 302 shares of the medical instruments supplier’s stock worth $25,000 after acquiring an additional 287 shares during the last quarter. Geneos Wealth Management Inc. lifted its stake in LeMaitre Vascular by 250.3% in the 1st quarter. Geneos Wealth Management Inc. now owns 557 shares of the medical instruments supplier’s stock worth $47,000 after purchasing an additional 398 shares in the last quarter. BI Asset Management Fondsmaeglerselskab A S bought a new position in shares of LeMaitre Vascular during the 1st quarter valued at about $50,000. US Bancorp DE grew its position in shares of LeMaitre Vascular by 36.0% during the first quarter. US Bancorp DE now owns 1,390 shares of the medical instruments supplier’s stock valued at $117,000 after purchasing an additional 368 shares in the last quarter. Finally, Strs Ohio bought a new stake in shares of LeMaitre Vascular in the first quarter worth about $168,000. Hedge funds and other institutional investors own 84.64% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on LMAT. Wall Street Zen raised LeMaitre Vascular from a “hold” rating to a “buy” rating in a research note on Saturday, November 22nd. Wells Fargo & Company lowered their target price on LeMaitre Vascular from $97.00 to $93.00 and set an “equal weight” rating for the company in a research report on Friday, November 7th. Barrington Research restated an “outperform” rating and issued a $95.00 price target on shares of LeMaitre Vascular in a research report on Wednesday, October 15th. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of LeMaitre Vascular in a research note on Wednesday. Finally, Cantor Fitzgerald reiterated a “neutral” rating and set a $95.00 price objective on shares of LeMaitre Vascular in a research report on Monday, November 10th. One equities research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and four have assigned a Hold rating to the company’s stock. According to MarketBeat, LeMaitre Vascular presently has a consensus rating of “Moderate Buy” and an average target price of $100.20.

LeMaitre Vascular Stock Down 0.5%

Shares of LMAT opened at $82.96 on Friday. The company has a quick ratio of 11.74, a current ratio of 13.96 and a debt-to-equity ratio of 0.46. The business has a fifty day moving average of $87.22 and a 200 day moving average of $87.07. The company has a market cap of $1.88 billion, a PE ratio of 40.27, a P/E/G ratio of 2.29 and a beta of 0.77. LeMaitre Vascular, Inc. has a 52-week low of $71.42 and a 52-week high of $107.22.

LeMaitre Vascular (NASDAQ:LMAT) last announced its earnings results on Thursday, November 6th. The medical instruments supplier reported $0.62 earnings per share for the quarter, beating the consensus estimate of $0.57 by $0.05. The business had revenue of $61.05 million for the quarter, compared to the consensus estimate of $62.18 million. LeMaitre Vascular had a net margin of 20.08% and a return on equity of 13.67%. The business’s revenue for the quarter was up 11.4% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.49 earnings per share. LeMaitre Vascular has set its FY 2025 guidance at 2.480-2.530 EPS. Q4 2025 guidance at 0.640-0.690 EPS. On average, sell-side analysts expect that LeMaitre Vascular, Inc. will post 1.94 EPS for the current year.

LeMaitre Vascular Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, December 4th. Shareholders of record on Thursday, November 20th will be paid a $0.20 dividend. The ex-dividend date of this dividend is Thursday, November 20th. This represents a $0.80 annualized dividend and a yield of 1.0%. LeMaitre Vascular’s dividend payout ratio (DPR) is presently 34.48%.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.